In 2022, Dr. Arturo Molina earned $1.07M in total compensation at Sutro Biopharma, including $662.50K salary and $402.00K bonus. Most recently acquired 26,250 shares in Nov 2023. Currently holds stock worth $7.86M. Led Sutro Biopharma as CEO for 4 years.
Compensation History
Annual executive compensation data for Dr. Arturo Molina, including salary, bonuses, and stock awards.
Year
2022
Total Compensation
$1.07M
Salary
$662.50K
Bonus
$402.00K
Other
$8.27K
Salary
$662.50KBoard Justification
The compensation philosophy emphasizes pay for performance, aligning executive compensation with company performance and market practices.
Bonus
$402.00KBoard Justification
The bonus is based on the achievement of corporate goals set by the Compensation Committee, with an overall achievement level of 100% for 2022.
Other Compensation
$8.27KBoard Justification
Other compensation includes health benefits and other minor compensations.
Restricted Stock
Board Justification
No stock was reported as vested in 2022 for the CEO.
Performance Metrics
The performance metrics include achievement of corporate goals related to development, research, financial, and operational milestones.
Dr. Arturo Molina
Ex-CEO of Sutro Biopharma
Sector of Economy
Healthcare
CEO of Sutro Biopharma for
4 years 2 months (Jan 2021 - Mar 2025)
Previous Experience
Chief Medical Officer at Sutro Biopharma, Inc.
Other Sutro Biopharma CEOs
Holdings
Track Dr. Arturo Molina's stock holdings and portfolio value over time.
Total Stock Sold
$30.10K
$30.10K
1,848 PTGX shares
What if they kept their stock?
If Dr. Arturo Molina didn't sell their stock, today they would have:
Extra PTGX1,848 shares worth $170.48K.
This is 466.3% and $140.37K more than what they got when they sold the stock.
Insider Trading
Dr. Arturo Molina's recent stock transactions, purchases, and sales filed with the SEC.
26,250 shares
PTGX
Nov 15, 2023
Received
$30.01K
PTGX at $16.24/share
Nov 15, 2023
Sale
3,125 shares
PTGX
Jan 16, 2023
Received
21,250 shares
PTGX
Nov 15, 2022
Received
$50.00K
STRO at $7.75/share
May 14, 2020
Purchase
Rivals
Compare Dr. Arturo Molina with competitor CEOs and industry peers.